Roy S. Herbst, MD, PhD | Authors

Articles

Testing Positive Messaging in Smoking Cessation Counseling for Lung Cancer

April 05, 2017

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses an ongoing trial at Yale Cancer Center exploring the use of positive messaging in smoking cessation counseling for lung cancer during the AACR Annual Meeting.

KEYNOTE-010 Shows Overall Survival Benefit of Pembrolizumab in NSCLC

December 08, 2016

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.

Nivolumab and Future Biomarkers in NSCLC

June 12, 2015

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (medical oncology), professor of Pharmacology, chief, Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, associate director, Translational Research, Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the results of the CheckMate-057 trial, which examined nivolumab in patients with NSCLC, and possible biomarkers that could be identified.